Investor Presentaiton

Investor presentation ADA 2019 Slide 26 Amylin AM833 could become the next step in getting closer to the ambition of >20% weight loss Phase 1b amylin and semaglutide combination multiple dose trial Randomised: 80 people with obesity Cohort 5 - QW sema + QW AM833 Dose E 4* 4-week escalation steps (fixed ratio) Cohort 4 - QW sema + QW AM833 Dose D 4* 4-week escalation steps (fixed ratio) - Cohort 3 QW sema + QW AM833 Dose C 4* 4-week escalation steps (fixed ratio) Cohort 2 - QW sema + QW AM833 Dose B 4* 4-week escalation steps (fixed ratio) Cohort 1 QW sema + QW AM833 Dose A 4*4-week escalation steps (fixed ratio) 20 weeks treatment Phase 2 dose finding trial Randomised: 700 people with obesity AM833, 4.5 mg QW AM833, 2.4 mg QW AM833, 1.2 mg QW AM833, 0.6 mg QW AM833, 0.3 mg QW Liraglutide, 3.0 mg QD Trial objective ~19 months To assess the safety, tolerability, and PK properties, and to explore PD effects of multiple subcutaneous doses of amylin AM833 initiated simultaneously with semaglutide in people with overweight or obesity (BMI 27-39.9 kg/m2) Trial rationale Placebo Diet and physical activity counselling 26 weeks + 6 weeks follow-up To find optimal dose of sc. administered amylin AM833 QW for weight loss in people being overweight or with obesity (BMI 27-39.9 kg/m2) Primary endpoint Change from baseline to week 26 in body weight (%) Trial initiation: Q1 2019 novo nordisk QW: once-weekly; sema: semaglutide; sc: subcutaneous

View entire presentation